EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis — the European Renal Association (ERA) — Immunonephrology Working Group (ERA-IWG) perspective

Eleni Frangou², Annette Bruchfeld²,³, Gema M. Fernandez-Juarez³, Jürgen Floege⁵, Dimitrios Goumenos⁶, Sarah M. Moran⁷, Stefanie Steiger⁶, Kate I. Stevens⁹, Kultigin Turkmen¹⁰, Andreas Kronbichler¹¹

¹Department of Nephrology, Limassol General Hospital, Limassol, Cyprus; University of Nicosia Medical School, Nicosia, Cyprus
²Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
³Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden
⁴Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain; Instituto de Investigación la Paz, IDiPaz, Spain
⁵Division of Nephrology, RWTH Aachen University Hospital, Aachen, Germany
⁶Department of Nephrology and Renal Transplantation, Patras University Hospital, Patras, Greece
⁷Cork University Hospital, University College Cork, Cork, Ireland
⁸Renal Division, Department of Medicine IV, Ludwig-Maximilians-University Hospital Munich, Ludwig-Maximilians-University Munich, Germany
⁹Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK
¹⁰Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey
¹¹Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria

**Figure 1. Specific considerations when evaluating the optimal currently approved add-on therapy of a patient with active lupus nephritis (LN) class III–V**

Notes: BEL — belimumab; eGFR — estimated glomerular filtration rate; i.v. — intravenous; s.c. — subcutaneous; VCS — voclosporin.